Work

Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.

Year: 2021
Type: article
Abstract: designed the first OV-BiTE in 2014, which remarkably eradicated tumors in mice. Here we review the latest development of the structure, function, preclinical studies and/or clinical trials of BiTE and OV-BiTE and provide perspective views for optimizing the design of OV-BiTE. There is no doubt that OV-BiTE is becoming an exciting new platform for tumor immunotherapy and will enter clinical trial soon. Exploring the therapeutic effects and safety of OV-BiTE for synergistic tumor immunotherapy will bring new hope to tumor patients.
Language: English
Subfield: Genetics
Open Access status: green
OpenAlex ID: W3181883167
FWCI: 2.174
Cites: 118
Cited by: 34
Related to: 10